BioMarin Eyes European Market for Gene Therapy After US Setback


Share post:

July 20, 2022, 4:00 AM

BioMarin Pharmaceutical Inc. expects European patients to begin receiving its gene therapy for a life-threatening blood-clotting disorder before the end of the year, raising the drugmaker’s hopes it can succeed where rival Bluebird Bio Inc. faltered.

The one-time infusion for hemophilia could gain European approval at the end of August after getting a key recommendation in June from a regulatory committee, BioMarin Chief Commerical Officer Jeff Ajer said in an interview. The company will then make a country-by-country push to persuade health systems to pay for it, starting with Germany, with broader agreements likely taking about a year to clinch, …


Please enter your comment!
Please enter your name here


Related articles

Smoke shop worker shot in dispute on Lower East Side

LOWER EAST SIDE, Manhattan (WABC) — A smoke shop worker was shot during a dispute that spilled...

Patriots QB Jones suffered ‘pretty severe’ high-ankle sprain

Mac Jones has already battled a host of injuries during his sophomore season in the NFL....

On the disappearance of American starter homes | News

anchor Historic postcard of a Levittown, Long Island home from the 1950s. Image courtesy Mark Mathosian/Flickr. (CC BY-NC-SA...
English English Somali Somali